Clinical promise of new hematopoietic growth factors: M-CSF, IL-3, IL-6.
Hematopoietic growth factors are reaching maturity in clinical trials. There is a wide spectrum of disorders of bone marrow dysfunction that can be effectively treated by currently available hematopoietic growth factors. Newer growth factors are entering clinical trials. rhM-CSF has a variety of biological activities. It may be useful in hematology/oncology and infectious disease settings. Recombinant human interleukin-3 (rhIL-3) has undergone extensive trials in nonhuman primates that suggest that this hematopoietin is a potent stimulus of bone marrow function following chemotherapy and may be synergistic with other growth factors, such as rhGM-CSF. Other pleotrophic hematopoietic growth factors, such as interleukin-6, are currently being developed and may exert a wide spectrum of activities in disease states.
Garnick
M B
MB
Genetics Institute, Inc., Cambridge, Massachusetts.
O'Reilly
R J
RJ
D000208:Acute Disease; D000818:Animals; D000920:Antibody-Dependent Cell Cytotoxicity / Q000187:drug effects; D016026:Bone Marrow Transplantation; D003115:Colony-Stimulating Factors / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use*; D004341:Drug Evaluation; D004353:Drug Evaluation, Preclinical; D006410:Hematopoiesis / Q000187:drug effects; D006801:Humans; D007377:Interleukin-3 / Q000494:pharmacology / Q000627:therapeutic use*; D015850:Interleukin-6 / Q000494:pharmacology / Q000627:therapeutic use*; D007951:Leukemia, Myeloid / Q000188:drug therapy; D016173:Macrophage Colony-Stimulating Factor; D011323:Primates; D011994:Recombinant Proteins / Q000494:pharmacology / Q000627:therapeutic use
D003115:Colony-Stimulating Factors; D007377:Interleukin-3; D015850:Interleukin-6; D011994:Recombinant Proteins; D016173:Macrophage Colony-Stimulating Factor